tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immunome initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Immunome (IMNM) with a Buy rating and $26 price target The firm says Immunome is developing best- or first-in-class targeted oncology therapeutics. Goldman is positive into the Phase 3 RINGSIDE results in patients with desmoid tumors, with data expected at the end of 2025. Varegacestat is “differentiated” over Merck KGaA’s Ogsiveo, with best-in-class potential, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1